Cosentyx® is the first new biologic treatment for hidradenitis suppurativa in nearly a decade, offering clinically meaningful results across the most debilitating. | June 1, 2023
The European Medicines Agency said on Friday it had recommended revoking marketing authorisation for Novartis sickle cell disease drug Adakveo.. | May 26, 2023
May 26, 2023 Basel, May 26, 2023 - The European Medicines Agency s Committee for Medicinal Products for Human Use has recommended the revocation of the conditional. | May 26, 2023
By Adria Calatayud Novartis s Sandoz said Thursday that the European Medicines Agency has accepted its marketing-authorization application for biosimilar drug denosumab, which is indicated. | May 25, 2023
In his latest research note, analyst Richard Vosser confirms his recommendation. The broker JP Morgan is keeping its Neutral rating. The target price is still set at CHF 92. | May 19, 2023